Clinical Neurology and Neurosurgery
Volume 111, Issue 10 , Pages 864-867 , December 2009

Severe dopaminergic pathways damage in a case of chronic toluene abuse

  • Sokratis G. Papageorgiou

      Affiliations

    • Department of Neurology, Eginition Hospital, Medical School, Athens National University, Athens, Greece
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Eginition Hospital, University of Athens, 74, Vassilissis Sofias Avenue, 11528 Athens, Greece. Tel.: +30 2107289404/6977446034; fax: +30 2107216474.
    • ,
  • Evgenia Karantoni

      Affiliations

    • Department of Neurology, Eginition Hospital, Medical School, Athens National University, Athens, Greece
    • ,
  • Dionysios Pandis

      Affiliations

    • Department of Neurology, Eginition Hospital, Medical School, Athens National University, Athens, Greece
    • ,
  • Anastasios V. Kouzoupis

      Affiliations

    • Department of Psychiatry, Eginition Hospital, Medical School, Athens National University, Athens, Greece
    • ,
  • Nikolaos Kalfakis

      Affiliations

    • Department of Neurology, Eginition Hospital, Medical School, Athens National University, Athens, Greece
    • ,
  • Georgios S. Limouris

      Affiliations

    • Nuclear Medicine Division, Radiology Department, Aretaieio Hospital, Medical School, Athens National University, Athens, Greece

Received 26 November 2008 ,Revised 29 June 2009 ,Accepted 4 July 2009.

References 

  1. Aydin K, Sencer S, Demir T, Ogel K, Tunaci A, Minareci O, et al. Cranial MR findings in chronic toluene abuse by inhalation. AJNR Am J Neuroradiol. 2002;23:1173–1179
  2. Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. Neuroimaging in drug and substance abuse. Part II. Opioids and solvents. Top Magn Reson Imaging. 2005;16:239–245
  3. Kamran S, Bakshi R. MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images. Neuroradiology. 1998;40:519–521
  4. Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol. 2004;63:1–12
  5. EKTEPN . Annual report on drugs and alcohol use in Greece—article in Greek. Athens: EPIPSY; 2007;166 pp.
  6. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–510
  7. Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. Neurol Sci. 2006;27:397–401
  8. Paphiti MISP, Lamprakos L, Panayides C, Rousopoulos K, Stavraka A, Limouris GS. Comparison of specific binding index of regional DaTSCAN imaging vs MRI stratial volumetric measurements. European Journal of Nuclear Medicine and Molecular Imaging. 2007;34:253–411[Annual Congress of the European Association of Nuclear Medicine Copenhagen Denmark]
  9. Uitti RJ, Snow BJ, Shinotoh H, Vingerhoets FJ, Hayward M, Hashimoto S, et al. Parkinsonism induced by solvent abuse. Ann Neurol. 1994;35:616–619
  10. Gautschi OP, Cadosch D, Zellweger R. Postural tremor induced by paint sniffing. Neurol India. 2007;55:393–395
  11. Deleu D, Hanssens Y. Cerebellar dysfunction in chronic toluene abuse: beneficial response to amantadine hydrochloride. J Toxicol Clin Toxicol. 2000;38:37–41
  12. Miyagi Y, Shima F, Ishido K, Yasutake T, Kamikaseda K. Tremor induced by toluene misuse successfully treated by a Vim thalamotomy. J Neurol Neurosurg Psychiatry. 1999;66:794–796
  13. Rosenberg NL, Grigsby J, Dreisbach J, Busenbark D, Grigsby P. Neuropsychologic impairment and MRI abnormalities associated with chronic solvent abuse. J Toxicol Clin Toxicol. 2002;40:21–34
  14. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415–1423
  15. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424–438
  16. Stengard K, Hoglund G, Ungerstedt U. Extracellular dopamine levels within the striatum increase during inhalation exposure to toluene: a microdialysis study in awake, freely moving rats. Toxicol Lett. 1994;71:245–255
  17. Kondo H, Huang J, Ichihara G, Kamijima M, Saito I, Shibata E, et al. Toluene induces behavioral activation without affecting striatal dopamine metabolism in the rat: behavioral and microdialysis studies. Pharmacol Biochem Behav. 1995;51:97–101
  18. Edling C, Hellman B, Arvidson B, Andersson J, Hartvig P, Lilja A, et al. Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects. Int Arch Occup Environ Health. 1997;70:180–186
  19. Hageman G, van der Hoek J, van Hout M, van der Laan G, Steur EJ, de Bruin W, et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol. 1999;246:198–206
  20. Kornhuber J, Weller M. Neuroleptic malignant syndrome. Curr Opin Neurol. 1994;7:353–357
  21. Gerasimov MR, Schiffer WK, Marstellar D, Ferrieri R, Alexoff D, Dewey SL. Toluene inhalation produces regionally specific changes in extracellular dopamine. Drug Alcohol Depend. 2002;65:243–251
  22. Riegel AC, French ED. Abused inhalants and central reward pathways: electrophysiological and behavioral studies in the rat. Ann NY Acad Sci. 2002;965:281–291

PII: S0303-8467(09)00175-9

doi: 10.1016/j.clineuro.2009.07.007

Clinical Neurology and Neurosurgery
Volume 111, Issue 10 , Pages 864-867 , December 2009

Article Tools

* Image Usage & Resolution